Medicine composition containing inhibitor of angiotonase and phenoxy acid compounds

An angiotensin and composition technology, applied in the field of pharmaceutical preparation, can solve the problems of preventing and treating hypertension combined with hyperlipidemia and the like without discovering ACEI and phenoxy acid drugs, achieve a good market prospect, prevent or delay damage, improve The effect of patient compliance

Active Publication Date: 2011-06-22
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In the patent and scientific literature, it is not found that the combination of ACEI and phenoxy acid drugs is used for the prevention and treatment of hypertension complicated with hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. Effects of a pharmaceutical composition containing benazepril hydrochloride and fenofibrate on blood pressure and blood lipids in hypertensive rats with hyperlipidemia

[0033] The left renal artery of SD rats was narrowed with a 0.2mm silver clip, and the blood pressure of the rats increased by more than 140mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. Feed high-fat feed to hypertensive rats (the formula is: cholesterol 1%, propylthiouracil 0.2%, sodium cholate 0.3%, lard 10%, basal feed 88.5%), normal control group rats are fed with common feed. After 4 weeks, blood pressure (systolic blood pressure SBP, diastolic blood pressure DBP) of the rats was measured, and blood samples were collected to measure serum cholesterol (CHO), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Low-density lipoprotein (VLDL). According to blood pressu...

Embodiment 2

[0047] Example 2. Effects of a pharmaceutical composition containing cilazapril and ciprofibrate on hypertensive rats with hyperlipidemia

[0048] The left renal artery of SD rats was narrowed with a 0.2mm silver clip, and the blood pressure of the rats increased by more than 140mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. The hypertensive rats were fed high-fat feed (same as in Example 1), and the rats in the normal control group were fed common feed. After 4 weeks, the blood pressure (SBP, DBP) of the rats was measured, and blood was collected to measure serum CHO, TG, HDL, LDL, and VLDL. According to blood pressure and blood lipid levels (mainly DBP, TG, VLDL), hypertensive rats were divided into model group, cilazapril group (0.25mg / kg), ciprofibrate group (10mg / kg), Li + ciprofibrate group (0.25mg / kg+10mg / kg), 20 rats in each group, administered by intragastric administration, with ...

Embodiment 3

[0062] Example 3. Effects of Compositions Containing Ramipril and Benclofibrate on Blood Pressure and Blood Lipids in Rats with Hypertension and Hyperlipidemia

[0063] The left renal artery of SD rats was narrowed with a 0.2mm silver clip, and the blood pressure of the rats increased by more than 140mmHg after 8 to 10 weeks, and they were considered hypertensive animals. Another 20 normal rats were used as the normal control group. Rats with high blood pressure were fed high-fat feed (the same formula as in Example 1), and rats in the normal control group were fed with common feed. After 4 weeks, the blood pressure (SBP, DBP) of the rats was measured, and blood was collected to measure serum CHO, TG, HDL, LDL, and VLDL. According to blood pressure and blood lipid levels (mainly DBP, TG, VLDL), hypertensive rats were divided into model group, ramipril group (1mg / kg), benzclofibrate group (10mg / kg), ramipril group +Benzclofibrate group (1mg / kg+10mg / kg), 20 rats in each group, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composite medicine for preventing, treating and relaxing hypertension, hyperlipemia and the cardiovascular and cerebrovascular diseases contains ancovenin or its active metabolite or its salt and phenoxylic acid compound or its active metabolite or its salt or its ester.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing an angiotensin-converting enzyme inhibitor and a phenoxy acid compound, and the use of the pharmaceutical composition in preparing medicine. belongs to the field of pharmacy. Background technique [0002] Epidemiological studies have found that many people have high blood pressure and high blood lipids at the same time, and these people have a high risk of cardiovascular diseases such as coronary heart disease, myocardial infarction, and stroke, and cardiovascular diseases account for the first cause of human death. It is estimated that 30 million American patients have been diagnosed with these two high-risk factors; in China, a cross-sectional survey of 711 hypertensive patients with hyperlipidemia found that 186 hypertensive patients with hyperlipidemia, the disease The rate is 26.2%, which is significantly higher than the population level; and the prevalence rate of cardiovascular an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/401A61K9/16A61K9/20A61K9/48A61P9/12A61P9/10A61P9/04A61P3/06A61P3/04A61P3/10A61P3/00A61P13/12A61P27/02
Inventor 段炎炎王琳琳李莉徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap